Document resource
Background and Importance Neovascular age-related macular degeneration (nAMD) is a chronic, progressive retinal disease and one of the leading causes of vision loss in older adults. Although anti-vascular endothelial growth factor (VEGF) therapies have improved outcomes, there remains a need for treatments that provide both high efficacy and extended durability. Faricimab, a bispecific antibody targeting VEGF-A and Ang-2, offers the potential for longer treatment intervals, but real-world data remain limited.Aim and Objectives To evaluate the real-world effectiveness of faricimab in patients with nAMD, analysing visual outcomes and treatment patterns over one year.Material and Methods A retrospective study was conducted including patients with nAMD treated with faricimab between July 2024 and July 2025 in a tertiary hospital. Eligible patients had completed at least three loading doses. Data collected included the number of patients and treated eyes, demographic characteristics, treatment status (naïve or switch), and best-corrected visual acuity (BCVA, logMAR) at baseline, after loading (4 months), and at the last ophthalmology visit. The dosing interval (in weeks) at the last visit was also recorded.Results A total of 92 eyes from 82 patients were analysed. Mean age was 79.9 ± 6.5 years, and 48.9% were female. Overall, 93.5% were switch and 6.5% naïve at faricimab initiation. Mean BCVA (logMAR) was 0.42 ± 0.31 at baseline, 0.40 ± 0.26 after loading (~4 months), and 0.41 ± 0.30 at the last visit. The mean injection interval at the last visit was 7.9 ± 2.5 weeks. Grouped by regimen, Q4–Q6W included 29 eyes (31.5%), Q8W 35 eyes (38.0%), and Q10–Q12W 25 eyes (27.2%). In three eyes (3.3%) treatment was not continued: two switched to another anti-VEGF and one was suspended due to patient fragility.Conclusion and Relevance In real-world clinical practice, our study showed that faricimab maintained stable visual outcomes over one year, with a mean treatment interval shorter than those reported in pivotal clinical trials. The effectiveness and durability observed in our cohort were lower than those seen in controlled studies, reflecting the variability encountered in everyday clinical settings. Larger real-world studies with longer follow-up are warranted to confirm these findings and to optimise treatment strategies.Conflict of Interest No conflict of interest